Close Menu

NEW YORK – Oncocyte said Thursday that it has reached agreements for select institutional investors and other parties to purchase an aggregate of about 5.1 million shares of the company’s common stock at $1.70 per share.

Net proceeds from the financing, which will close no later than November 15, are expected to be about $8.5 million, OncoCyte wrote in a document filed with the US Securities and Exchange commission.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.